Karyopharm Therapeutics Profit Margin

Karyopharm Therapeutics (KPTI) currently reports a profit margin of -153.28% as of June 2026. That compares with -96.53% in the prior-year period — down 58.8% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Karyopharm Therapeutics's profit margin history and peer comparisons.

Karyopharm Therapeutics's profit margin decreased from -96.53% to -153.28% — a 58.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Karyopharm Therapeutics's profit margin of -153.28% is lower than the Healthcare sector average of 9.48%. That is roughly 1716.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Karyopharm Therapeutics's current -153.28% should be judged against Healthcare norms (sector average: 9.48%) and against KPTI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -153.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Karyopharm Therapeutics, and consider following KPTI for alerts when major investors trade the stock.